PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2026-01-06

Date Title Company
06-Jan-2026 Thermo Fisher Scientific to Present at the J.P. Morgan 2026 Healthcare Conference Businesswire
06-Jan-2026 Encellin Announces Interim Clinical Results Showing First-in-Human Non-Fibrotic Engraftment and Viable Encapsulated Human Islets in Subjects with Type 1 Diabetes Businesswire
06-Jan-2026 3T Biosciences Announces Appointments of Behzad Kharabi, M.D., as Chief Medical Officer, and Parker Institute for Cancer Immunotherapy (PICI) CEO Karen Knudsen, MBA, Ph.D., to Board of Directors Businesswire
06-Jan-2026 Thermo Fisher Scientific Launches CorEvitas Obesity Registry to Advance Real-World Evidence in Treatment Outcomes Businesswire
06-Jan-2026 Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens Businesswire
06-Jan-2026 Viridian Therapeutics Prepares for Transformational 2026 Businesswire
06-Jan-2026 SpliceBio Appoints Don Munoz as Chief Financial Officer Businesswire
06-Jan-2026 OncoNano Medicine Announces Research Collaboration with Gilead to Apply ON-BOARD™ Delivery Technology to Gilead’s Drug Candidate Businesswire
06-Jan-2026 Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder Businesswire
06-Jan-2026 Lysoway Therapeutics Announces Phase I Readiness of Brain-Penetrant TRPML1 Agonist LW-1017 and Nomination of a TMEM175 Development Candidate Businesswire
06-Jan-2026 Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360 Businesswire
06-Jan-2026 Alloy Therapeutics Appoints Christian Cobaugh, Ph.D., as CEO of Alloy Genetic Medicines Businesswire
06-Jan-2026 HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma HUTCHMED
06-Jan-2026 Johnson & Johnson submits application to the European Medicines Agency for TECVAYLI®▼ (teclistamab) in combination with DARZALEX® (daratumumab) subcutaneous formulation for patients with relapsed/refractory multiple myeloma Johnson & Johnson
06-Jan-2026 Research award will accelerate research to map brain electrical circuits University of Nottingham
06-Jan-2026 ALST Signs Non-Disclosure Agreement with Major Toronto University for Proposed Allstar Sports Centre Development ACCESS Newswire
06-Jan-2026 LoQus23 Therapeutics nominates LQT-23 as first-in-class, oral drug candidate for Huntington’s Disease LoQus23 Therapeutics
06-Jan-2026 HUTCHMED Initiates Phase III Stage of the Ongoing Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naïve Pancreatic Ductal Adenocarcinoma HUTCHMED
06-Jan-2026 Biotium Launches GlycoLiner™ Cell Surface Glycoprotein Labeling Kits for Rapid and Selective Cell Surface Imaging Biotium
06-Jan-2026 Acesion Pharma starts Phase 2 trial of AP31969 in patients with atrial fibrillation Acesion Pharma